Convalescent Plasma News and Research

RSS

Study shows IgA antibodies play a significant role in neutralizing SARS-CoV-2

A recent paper by researchers from Australia, currently available on the medRxiv* preprint server, shows how Immunoglobulin A (IgA) antibodies in individuals who were infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contribute to the neutralization of the virus and its variants, even though this response is heterogeneous and less potent when compared to IgG antibodies.

13 Feb 2022

Dynamics and longevity of antibody response from COVID-19 convalescents across the clinical spectrum

Researchers investigated the dynamics and longevity of neutralizing antibody response up to 480 days after the onset of infection in convalescent COVID-19 patients.

9 Feb 2022

Greater neutralizing titers observed in vaccinated individuals with breakthrough Omicron infection

Researchers assess the neutralizing power of plasma samples collected from Omicron convalescent individuals who were either vaccinated or unvaccinated.

6 Feb 2022

Study finds that high-dose convalescent plasma does not improve outcomes for severe COVID-19

A randomized controlled trial assesses the efficacy and safety of high-dose convalescent plasma in the treatment of severe COVID-19.

1 Feb 2022

Study assesses anti-SARS-CoV-2 antibody response to mRNA-1273 vaccination over time

A new study has assessed the antibody responses to the mRNA-1273 Moderna vaccine over time.

31 Jan 2022

Hospitalized COVID-19 patients may derive modest benefit from convalescent plasma, study shows

Transfusions of blood plasma donated by people who have recovered from COVID-19 may help patients hospitalized with the virus, a new international study shows.

25 Jan 2022

Development of a glycoprotein multi-epitope subunit vaccine candidate against South-African SARS-CoV-2 strains

In a new study, scientists focused on the SARS-CoV-2 Beta variant and used computational methods to design and develop effective glycoprotein multi-epitope subunit vaccine candidates, based on the old and the new Beta virus strains.

20 Jan 2022

Variants of SARS-CoV-2 and preventive strategies

A recent review article published in the journal Advanced Science reviewed the features of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants. Using a physical and materials science perspective, the review also summarizes the most significant variants of SARS-CoV-2 encountered to date as well as possible preventive strategies.

19 Jan 2022

SARS-CoV-2 vaccination of convalescents suggested to boost neutralization capacity against variants

A new study assessed the neutralization capacity of sera from convalescents—some even vaccinated—against the Wuhan (D614G), Delta and Omicron variants of SARS-CoV-2.

19 Jan 2022

Study demonstrates that intra-host SARS-CoV-2 variants with reduced infectivity are developed during infection

A new paper discusses the appearance of quasi-species in a single host with prolonged infection, with different rates of infectivity and sensitivity to neutralization by antibodies elicited by the Pfizer vaccine or those present in convalescent plasma.

17 Jan 2022

SARS-CoV-2 Delta sublineage AY.4.2 shows no increase in cell entry or antibody evasion

Researchers from Germany, in their recent study published in the journal Cellular & Molecular Immunology, have evaluated the mutations in the S protein of one such SARS-CoV-2 strain, a Delta sublineage AY.4.2, which is currently expanding in the UK, and have found that it neither contains any potential for increased cell entry nor antibody escape.

10 Jan 2022

NYBC discovers novel small-molecule pancoronavirus fusion inhibitors

New York Blood Center has published a study that reports the discovery of highly potent small molecules with the ability to inhibit COVID-19 in infected individuals.

9 Jan 2022

Serological antibody response to SARS-CoV-2 infection at a population level

The scientists in this study used pooled convalescent serum to examine the serologic response in a population at risk of infection.

6 Jan 2022

Efficacy of COVID-19 convalescent plasma therapy in patients with hematological malignancies and COVID-19

Scientists recently demonstrated the efficacy of COVID-19 convalescent plasma therapy in improving the survival rate among patients with B-cell lymphoid malignancy and COVID-19.

5 Jan 2022

New study on NAbs against SARS-CoV-2 Omicron variant after vaccination or infection

A recent study suggests neutralizing antibody responses against variants of concern, including Omicron, differs significantly between vaccinated and naturally infected individuals. The research, posted to the medRxiv* preprint server, focused on vaccinated individuals who are pregnant — an understudied group in COVID-19 research.

4 Jan 2022

Production of molecular probes of spike and subdomains for all SARS-CoV-2 variants

Researchers designed molecular probes of diverse SARS-CoV-2 variants and evaluated their antibody binding specificity.

3 Jan 2022

Researchers suggest hybrid convalescent plasma therapy neutralizes the omicron variant

New research suggests convalescent plasma from unvaccinated donors is not effective against the Omicron variant, however, “hybrid” convalescent plasma from donors who recovered from COVID-19 infection and are vaccinated provides considerable antibody protection.

29 Dec 2021

Early administration of SARS-CoV-2 convalescent plasma reduces outpatient hospitalizations

The results of a nationwide, multicenter clinical trial led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health provides solid evidence for the use of plasma from convalescent patients — those who have recovered from the disease and whose blood contains antibodies against SARS-CoV-2, the virus that causes COVID-19 — as an early treatment.

21 Dec 2021

Study suggests convalescent plasma appears safe but does not prevent SARS-CoV-2 infection

A new study assesses the safety and efficacy of SARS-CoV-2 convalescent plasma containing high titers of anti-SARS-CoV-2 antibodies as PEP.

16 Dec 2021

T-cell immune response in previously infected and vaccinated individuals effective against SARS-CoV-2 Omicron variant

New findings illustrate that despite the continuous pattern of the ongoing evolution of SARS-CoV-2, it has not resulted in any significant accumulation of CD8+ T-cell escape mutations.

15 Dec 2021